Psoriasis is a difficult to treat chronic skin condition that could be limiting to quality of life. Here, authors present results of the phase 2 randomized clinical trial KNOCKOUT (NCT05283135) in which they treated patients with moderate-to-severe plaque psoriasis with higher-than-approved doses of risankizumab, an interleukin-23 inhibitor, to show high skin clearance rates and decreased tissue resident memory T cell numbers in the lesional skin.
- Andrew Blauvelt
- Rundong Jiang
- Benjamin D. Ehst
